GlassScriptPhysician profile
Amandeep Goyal
NPI 1710273248
$4,216.42
in general payments reported to CMS, 2019-2025
17 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $75.20 · 2021: $491 · 2022: $633 · 2023: $372 · 2024: $1,708 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754 · Travel and Lodging: $591 · Education: $456 · Grant: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.93 |
| Travel and Lodging | $591.01 |
| Education | $455.95 |
| Grant | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,139.39 | 2021-2025 | Ensite, Ensite Precision, Cardiomems |
| Medtronic, INC. | $736.38 | 2021-2024 | Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $431.36 | 2020-2025 | Lifevest |
| Abiomed | $276.99 | 2022-2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $253.93 | 2023-2024 | Camzyos, Eliquis |
| Amgen INC. | $250.81 | 2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $236.75 | 2022-2025 | Amvuttra |
| Boston Scientific Corporation | $215.80 | 2024-2025 | General - Structural Heart |
| Siemens Medical Solutions USA, INC. | $144.92 | 2025 | Magnetom Sola |
| Philips North America LLC | $143.91 | 2024 | (Bh4) Igt Devices Undivided |
| Sanofi-Aventis U.S. LLC | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $101.13 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $78.54 | 2021 | |
| Edwards Lifesciences Corporation | $26.12 | 2024 | |
| Novo Nordisk INC | $20.37 | 2023 | Ozempic |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amandeep Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.